ANI Pharmaceuticals (ANIP) said it completed its planned acquisition of Alimera Sciences (NASDAQ:ALIM). Under the terms of ...
Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a ...
The acquisition strengthens the company’s rare disease segment, and adds 2 durable commercial assets, Iluvien and Yutiq with ...
ANI and Alimera Scheduled the Closing for September 16, 2024PRINCETON, N.J. and ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- ...
In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on ANI Pharmaceuticals (ANIP – Research Report), ...
ANI Pharmaceuticals acquiring Alimera Sciences for $5.50 per share with potential for $0.50 per share CVR, offering an ...
Alimera Sciences files lawsuit against ANI Pharmaceuticals over failed merger, causing stock to plummet 25% in premarket ...
Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a pro forma basis Adds two durable commercial assets ILUVIEN® and YUTIQ ...
PRINCETON - ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), a diversified biopharmaceutical company, announced today the finalization of its acquisition process for Alimera (NASDAQ:ALIM) Sciences ...
ANI and Alimera Scheduled the Closing for September 16, 2024 PRINCETON, N.J. & ATLANTA, September 11, 2024--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (NASDAQ: ANIP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback